Risk stratification of patients with right ventricular infarction: is there a need for a specific risk score?

H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol 2001; 38: 1644–50. [13] Buerke M, Rupprecht HJ, Vom DJ et al. Sodium–hydrogen exchange inhibition: novel strategy to prevent myocardial injury following ischemia and reperfusion. Am J Cardiol 1999; 83: G19–G22. [14] Murohara Y, Yui Y, Hattori R, Kawai C. Effects of superoxide dismutase on reperfusion arrhythmias and left ventricular function in patients undergoing thrombolysis for anterior wall acute myocardial infarction. Am J Cardiol 1991; 8: 765–7. [15] Flaherty JT, Pitt B, Gruber JW et al. Recombinant superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation 1994; 5: 1982– 91. [16] Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31–47. [17] Entman ML, Michael L, Rossen RD et al. Inflammation in the course of early myocardial ischemia. FASEB J 1991; 5: 2529–37. [18] Roberts R, DeMello V, Sobel BE. Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation 1976; 53(Suppl 3): 1204–6. [19] de Zwaan C, Kleine AH, Diris JHC, Glatz JFC, Wellens HJJ, Strengers PFW, Tissing M, Hack CE, van Dieijen-Visser MP, Hermens WT. Continuous 48-h C1-inhibitor treatment following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 2002; 23: 1670–1677.